Your browser is no longer supported. Please, upgrade your browser.
Settings
BBIO [NASD]
BridgeBio Pharma, Inc.
Index- P/E- EPS (ttm)-3.80 Insider Own6.00% Shs Outstand118.99M Perf Week1.16%
Market Cap8.19B Forward P/E- EPS next Y-3.05 Insider Trans-29.43% Shs Float96.67M Perf Month-19.67%
Income-448.70M PEG- EPS next Q-0.74 Inst Own81.60% Short Float10.86% Perf Quarter-20.95%
Sales8.20M P/S998.21 EPS this Y-53.40% Inst Trans3.01% Short Ratio9.73 Perf Half Y43.43%
Book/sh0.49 P/B112.49 EPS next Y-3.40% ROA-53.00% Target Price84.13 Perf Year107.69%
Cash/sh4.09 P/C13.48 EPS next 5Y- ROE-206.80% 52W Range25.24 - 73.50 Perf YTD-22.49%
Dividend- P/FCF- EPS past 5Y- ROI-88.40% 52W High-25.01% Beta-
Dividend %- Quick Ratio6.70 Sales past 5Y- Gross Margin- 52W Low118.38% ATR3.30
Employees385 Current Ratio6.70 Sales Q/Q-99.30% Oper. Margin- RSI (14)40.25 Volatility4.41% 5.78%
OptionableYes Debt/Eq8.25 EPS Q/Q-61.70% Profit Margin- Rel Volume0.47 Prev Close54.95
ShortableYes LT Debt/Eq8.22 Earnings- Payout- Avg Volume1.08M Price55.12
Recom1.80 SMA20-7.60% SMA50-13.88% SMA20013.78% Volume507,717 Change0.31%
Mar-22-21Reiterated Goldman Buy $83 → $91
Feb-22-21Resumed JP Morgan Overweight $78
Feb-09-21Resumed Goldman Buy $83
Jan-11-21Reiterated H.C. Wainwright Buy $64 → $87
Dec-10-20Reiterated H.C. Wainwright Buy $53 → $64
Jun-25-20Initiated BofA/Merrill Neutral $38
May-19-20Initiated BTIG Research Buy $49
Apr-13-20Initiated H.C. Wainwright Buy $50
Feb-19-20Initiated Mizuho Buy $51
Jul-26-19Initiated Raymond James Outperform $36
Jul-22-19Initiated SVB Leerink Outperform $34
Jul-22-19Initiated Piper Jaffray Overweight $50
Jul-22-19Initiated JP Morgan Overweight $38
Jul-22-19Initiated Jefferies Buy $38
Jul-22-19Initiated Goldman Buy $42
Jul-22-19Initiated BMO Capital Markets Outperform $49
Apr-13-21 07:45AM  
07:42AM  
07:40AM  
07:37AM  
07:35AM  
07:32AM  
07:30AM  
Apr-06-21 04:30PM  
Mar-31-21 11:46AM  
07:30AM  
Mar-20-21 11:00AM  
Mar-16-21 01:20PM  
Mar-02-21 04:30PM  
Mar-01-21 09:56AM  
05:17AM  
Feb-28-21 08:00AM  
Feb-26-21 08:46AM  
Feb-25-21 07:30AM  
Feb-24-21 04:01PM  
Feb-19-21 01:01PM  
07:30AM  
Feb-17-21 12:49PM  
Feb-12-21 08:00AM  
Feb-11-21 04:09PM  
Feb-05-21 04:30PM  
01:02AM  
Feb-02-21 07:30AM  
Jan-26-21 08:30AM  
Jan-25-21 11:04PM  
07:00AM  
Jan-19-21 04:01PM  
Jan-13-21 04:30PM  
Jan-08-21 06:56AM  
Jan-06-21 04:30PM  
10:53AM  
Jan-05-21 06:23AM  
Jan-04-21 11:42AM  
07:30AM  
Dec-26-20 10:05AM  
Dec-23-20 07:30AM  
Dec-19-20 04:11PM  
02:44PM  
Dec-17-20 11:08PM  
Dec-14-20 08:43PM  
09:10AM  
Dec-11-20 09:13PM  
Dec-07-20 08:30AM  
Dec-04-20 04:30PM  
11:46AM  
Dec-03-20 05:00PM  
06:27AM  
Dec-02-20 02:39PM  
Dec-01-20 07:30AM  
Nov-25-20 08:01AM  
Nov-13-20 07:30AM  
Nov-09-20 06:15PM  
Nov-07-20 07:58AM  
Nov-06-20 08:01AM  
Nov-05-20 09:05AM  
07:30AM  
Nov-04-20 04:30PM  
Oct-29-20 12:34PM  
Oct-27-20 05:00PM  
07:30AM  
Oct-23-20 04:44PM  
04:35PM  
Oct-21-20 07:30AM  
07:25AM  
Oct-16-20 04:25PM  
Oct-15-20 12:07PM  
Oct-07-20 01:45PM  
Oct-05-20 09:00PM  
01:46PM  
12:05PM  
10:03AM  
09:23AM  
09:06AM  
07:21AM  
07:04AM  
Oct-03-20 06:07AM  
Sep-29-20 04:23PM  
07:30AM  
Sep-22-20 07:30AM  
06:03AM  
Sep-21-20 07:30AM  
Sep-03-20 05:30PM  
Aug-12-20 04:30PM  
Aug-11-20 07:40AM  
07:35AM  
Jul-28-20 07:30AM  
Jul-15-20 07:30AM  
Jul-10-20 07:30AM  
Jul-06-20 04:30PM  
Jul-05-20 03:43PM  
Jun-25-20 10:10AM  
Jun-24-20 07:30AM  
Jun-18-20 07:35AM  
07:30AM  
Jun-11-20 07:00AM  
Jun-05-20 04:30PM  
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, a small molecule stabilizer of transthyretin, or TTR, that is in an ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor which is an ongoing Phase 2 clinical trial for the treatment of achondroplasia in pediatric patients; an AAV5 gene transfer product candidate for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD; and Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, an ongoing phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; The Regents of the University of California; Leidos Biomedical Research, Inc.; the University of California, San Diego; Johns Hopkins University and University of Florida; University of Colorado Anschutz Medical Campus; Salk Institute for Biological Studies; Maze Therapeutics; UC San Francisco; the Canadian Glycomics Network (GlycoNet); and the University of California, Davis. The company was founded in 2015 and is headquartered in Palo Alto, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Scott Randal W.DirectorFeb 17Buy62.5016,0001,000,00021,000Feb 18 06:21 PM
STEPHENSON BRIAN CSee RemarksFeb 17Buy62.508,000500,000300,043Feb 18 08:33 PM
KKR Genetic Disorder L.P.10% OwnerFeb 17Sale60.473,450,000208,617,36031,060,971Feb 17 05:36 PM
Turtle CameronSee RemarksDec 28Option Exercise6.6919,500130,50032,068Dec 29 09:14 PM
Turtle CameronSee RemarksDec 28Sale69.6019,5001,357,18412,568Dec 29 09:14 PM
SCHELLER RICHARD HSee RemarksDec 21Sale65.3260,4013,945,13745,860Dec 23 05:35 PM
SCHELLER RICHARD HSee RemarksDec 18Sale65.0730,0001,952,021106,261Dec 21 04:05 PM
SCHELLER RICHARD HSee RemarksDec 15Option Exercise17.0029,277497,709167,704Dec 17 04:05 PM
SCHELLER RICHARD HSee RemarksDec 15Sale60.3831,4431,898,417136,261Dec 17 04:05 PM
HENDERSON MICHAEL THOMASChief Business OfficerDec 01Option Exercise1.0510,00010,500284,211Dec 02 04:17 PM
HENDERSON MICHAEL THOMASChief Business OfficerDec 01Sale51.5210,000515,204274,211Dec 02 04:17 PM
Turtle CameronSee RemarksNov 25Option Exercise17.0074212,61413,310Nov 25 09:54 PM
Turtle CameronSee RemarksNov 25Sale47.2374235,04412,568Nov 25 09:54 PM
Turtle CameronSee RemarksNov 24Option Exercise17.004,25872,38616,826Nov 25 09:54 PM
Turtle CameronSee RemarksNov 24Sale47.004,258200,13712,568Nov 25 09:54 PM
HENDERSON MICHAEL THOMASChief Business OfficerNov 16Option Exercise1.0510,00010,500277,751Nov 18 07:43 PM
HENDERSON MICHAEL THOMASChief Business OfficerNov 16Sale45.0010,000450,000267,751Nov 18 07:43 PM
MCCORMICK FRANKChairman of OncologyNov 13Sale42.76100,0004,275,7691,200,468Nov 17 04:05 PM
Turtle CameronSee RemarksNov 05Option Exercise17.002,50042,50015,068Nov 09 04:05 PM
Turtle CameronSee RemarksNov 05Sale42.052,500105,12512,568Nov 09 04:05 PM
HENDERSON MICHAEL THOMASChief Business OfficerNov 02Option Exercise1.0510,00010,500277,751Nov 03 04:05 PM
HENDERSON MICHAEL THOMASChief Business OfficerNov 02Sale38.3610,000383,558267,751Nov 03 04:05 PM
HOMCY CHARLES JChairman of PharmaceuticalsOct 16Option Exercise17.0010,256174,3521,214,023Oct 19 09:14 PM
HOMCY CHARLES JChairman of PharmaceuticalsOct 16Sale41.0010,256420,4961,203,767Oct 19 09:14 PM
HENDERSON MICHAEL THOMASChief Business OfficerOct 01Option Exercise0.8010,0007,994277,751Oct 05 04:05 PM
HENDERSON MICHAEL THOMASChief Business OfficerOct 01Sale38.8310,000388,342267,751Oct 05 04:05 PM
Turtle CameronSee RemarksSep 30Option Exercise3.1414,50045,50027,068Oct 02 07:57 PM
HOMCY CHARLES JChairman of PharmaceuticalsSep 30Option Exercise17.0010,000170,0001,213,767Oct 01 04:05 PM
HOMCY CHARLES JChairman of PharmaceuticalsSep 30Sale38.0010,000380,0001,203,767Oct 01 04:05 PM
Turtle CameronSee RemarksSep 30Sale37.6914,500546,45812,568Oct 02 07:57 PM
HOMCY CHARLES JChairman of PharmaceuticalsSep 29Sale37.5018,200682,5001,203,767Sep 29 07:02 PM
HOMCY CHARLES JChairman of PharmaceuticalsSep 25Sale36.8381,0572,985,4551,221,967Sep 29 07:02 PM
HENDERSON MICHAEL THOMASChief Business OfficerSep 18Option Exercise0.2210,0002,212277,751Sep 22 07:05 PM
Turtle CameronSee RemarksSep 18Option Exercise17.002,50042,50015,068Sep 22 07:07 PM
HENDERSON MICHAEL THOMASChief Business OfficerSep 18Sale40.0010,000400,000267,751Sep 22 07:05 PM
Turtle CameronSee RemarksSep 18Sale42.012,500105,02412,568Sep 22 07:07 PM
SCHELLER RICHARD HSee RemarksSep 16Sale37.5025,000937,500138,427Sep 18 04:05 PM
Turtle CameronSee RemarksSep 15Option Exercise17.002,50042,50015,068Sep 16 06:38 PM
Turtle CameronSee RemarksSep 15Sale37.062,50092,65212,568Sep 16 06:38 PM
Turtle CameronSee RemarksSep 11Option Exercise0.342,00068014,568Sep 15 04:05 PM
Turtle CameronSee RemarksSep 11Sale35.022,00070,04712,568Sep 15 04:05 PM
HENDERSON MICHAEL THOMASChief Business OfficerSep 01Option Exercise0.1610,0001,600277,751Sep 03 04:06 PM
HENDERSON MICHAEL THOMASChief Business OfficerSep 01Sale28.7310,000287,334267,751Sep 03 04:06 PM
Kumar NeilCEO and PresidentAug 04Sale27.0213,943376,7602,085,372Aug 05 06:47 PM
STEPHENSON BRIAN CSee RemarksAug 04Sale27.252,53969,196287,116Aug 05 06:55 PM
HENDERSON MICHAEL THOMASChief Business OfficerAug 03Option Exercise0.1610,0001,600270,293Aug 05 06:03 PM
STEPHENSON BRIAN CSee RemarksAug 03Sale27.274,661127,092289,655Aug 05 06:55 PM
Kumar NeilCEO and PresidentAug 03Sale27.2766,0571,801,3062,099,315Aug 05 06:47 PM
HENDERSON MICHAEL THOMASChief Business OfficerAug 03Sale27.3710,000273,741260,293Aug 05 06:03 PM
Kumar NeilCEO and PresidentJul 02Sale30.2256,4451,706,0222,165,372Jul 06 07:18 PM
HENDERSON MICHAEL THOMASChief Business OfficerJul 01Option Exercise0.1610,0001,600270,293Jul 06 05:28 PM
STEPHENSON BRIAN CSee RemarksJul 01Sale30.9310,800334,053294,316Jul 06 05:29 PM
HENDERSON MICHAEL THOMASChief Business OfficerJul 01Sale30.9710,000309,701260,293Jul 06 05:28 PM
Kumar NeilCEO and PresidentJul 01Sale31.0987,0252,705,3352,221,817Jul 06 07:18 PM
Turtle CameronSee RemarksJun 30Option Exercise0.2310,0002,32019,823Jul 02 04:28 PM
Turtle CameronSee RemarksJun 30Sale32.6610,000326,6239,823Jul 02 04:28 PM
HENDERSON MICHAEL THOMASChief Business OfficerJun 08Sale30.0160618,185260,293Jun 10 04:12 PM
Kumar NeilCEO and PresidentJun 08Sale30.0110,600318,1252,308,842Jun 10 04:09 PM
STEPHENSON BRIAN CSee RemarksJun 08Sale30.002,00060,002305,116Jun 10 04:06 PM
STEPHENSON BRIAN CSee RemarksJun 03Sale30.041,60048,072307,116Jun 05 07:59 PM
Kumar NeilCEO and PresidentJun 03Sale30.055,930178,1732,319,442Jun 05 07:55 PM
HENDERSON MICHAEL THOMASChief Business OfficerJun 03Sale30.0478423,549261,399Dec 02 04:05 PM
Kumar NeilCEO and PresidentJun 01Sale29.1980,0002,335,3902,325,372Jun 03 04:06 PM
HENDERSON MICHAEL THOMASChief Business OfficerJun 01Sale29.372,58575,912261,683Jun 03 04:05 PM
STEPHENSON BRIAN CSee RemarksJun 01Sale29.367,200211,401308,716Jun 03 04:06 PM
KKR Genetic Disorder L.P.10% OwnerMay 28Sale33.392,389,69079,791,74934,510,971Jun 01 05:15 PM
HENDERSON MICHAEL THOMASChief Business OfficerMay 26Option Exercise1.0518,36519,283264,268May 27 04:57 PM
HENDERSON MICHAEL THOMASSee RemarksMay 05Sale30.471,46044,493162,362May 06 08:28 PM
STEPHENSON BRIAN CSee RemarksMay 05Sale30.495,706173,959315,916May 06 08:26 PM
Kumar NeilCEO and PresidentMay 05Sale31.0279,6002,469,4822,405,372May 06 08:21 PM
Kumar NeilCEO and PresidentMay 04Sale29.6839,6801,177,6852,484,972May 05 04:05 PM
STEPHENSON BRIAN CSee RemarksMay 04Sale30.001,49444,827321,622May 05 06:15 AM
HENDERSON MICHAEL THOMASSee RemarksMay 04Sale30.011,32039,613163,822May 05 06:13 AM
HENDERSON MICHAEL THOMASSee RemarksMay 01Sale29.272,58575,653165,142May 05 06:13 AM
STEPHENSON BRIAN CSee RemarksMay 01Sale29.237,200210,474323,116May 05 06:15 AM
Kumar NeilCEO and PresidentMay 01Sale29.1440,7201,186,4002,524,652May 05 04:05 PM
Turtle CameronSee RemarksApr 27Option Exercise17.002,00034,00011,823Apr 29 04:05 PM
Turtle CameronSee RemarksApr 27Sale32.012,00064,0289,823Apr 29 04:05 PM